EUVIMEDDescoperă EUVIMED
LeserbriefOpen access · CC BY 4.0

Optimized synthesis, polymer conjugation, and proof‐of‐concept studies of the gd‐IgA1 epitope for antibody‐scavenging therapies in IgA nephropathy

Clément Bechtler, Ouliana Barneoud-Rousset, Lijuan Pang, Kea Martin, Katrin F König, Pascal Hänggi, Nick Pearson, Daniel Ricklin

Chemical Biology & Drug Design · 2023

DOI: 10.1111/cbdd.14258 ↗

At a glance

Leserbrief in Chemical Biology & Drug Design, 2023. Written by Clément Bechtler and 7 co-authors. Institution: Molecular Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. Major MEDLINE topics: Glomerulonephritis, IGA. Cited 3 times so far (Crossref); 12 references. The full text is freely available (open access, CC BY 4.0). Funded by: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

IgA nephropathy (IgAN) is the most common glomerular autoimmune disease and has severe long‐term consequences for patients, with 40% of the patients eventually progressing to end‐stage renal disease. Despite the severity, no causal treatment is currently available. While the pathogenesis of IgAN is complex, disease severity is linked to autoantibodies against the gd‐IgA1 epitope, a stretch in the hinge region of IgA1 that lacks O ‐glycans and is found in the characteristic immune complexes deposited in the kidneys of IgAN patients. One elegant, causal approach would be to remove the anti‐gd‐IgA1 autoantibodies and consequently reduce the immune complex burden on the kidneys. The administration of synthetic polymers that present autoantigens in a multivalent manner have been established as promising therapeutic strategies in other autoimmune diseases and may be applied to IgAN. We here present an improved protocol for the synthesis of the gd‐IgA1 epitope, its successful coupling to a poly‐L‐lysine polymer and proof‐of‐concept experiments that the polymer‐bound synthetic glycopeptide is able to capture the IgAN autoantibodies, making this approach a promising way forward for developing a targeted treatment option for IgAN patients.

Subjects

MeSH terms (MEDLINE)

Glomerulonephritis, IGAHumansEpitopesImmunoglobulin AAutoantibodiesAntigen-Antibody ComplexGalactose

Author keywords

IgA nephropathyantibody scavengingautoantibodiesgd-IgA1glycopeptideglycopolymer

Substances

EpitopesImmunoglobulin AAutoantibodiesAntigen-Antibody ComplexGalactose

Authors and institutions

  • Molecular Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
  • Polyneuron Pharmaceuticals AG, Basel, Switzerland.
  • Division of Internal Medicine, University Hospital Basel, Basel, Switzerland.

Funding

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Cite

APA

Bechtler, C., Barneoud-Rousset, O., Pang, L., Martin, K., König, K. F., Hänggi, P., Pearson, N., & Ricklin, D. (2023). Optimized synthesis, polymer conjugation, and proof‐of‐concept studies of the gd‐IgA1 epitope for antibody‐scavenging therapies in IgA nephropathy. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14258

Vancouver

Bechtler C, Barneoud-Rousset O, Pang L, Martin K, König KF, Hänggi P, et al. Optimized synthesis, polymer conjugation, and proof‐of‐concept studies of the gd‐IgA1 epitope for antibody‐scavenging therapies in IgA nephropathy. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14258

BibTeX
@article{Bechtler2023,
  author = {Bechtler, Clément and Barneoud-Rousset, Ouliana and Pang, Lijuan and Martin, Kea and König, Katrin F and Hänggi, Pascal and Pearson, Nick and Ricklin, Daniel},
  title = {Optimized synthesis, polymer conjugation, and proof‐of‐concept studies of the gd‐IgA1 epitope for antibody‐scavenging therapies in IgA nephropathy},
  journal = {Chemical Biology & Drug Design},
  year = {2023},
  doi = {10.1111/cbdd.14258}
}
Start for free →